Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 5/20 | 0.47 |
| ▸ | GPR119 | Q8TDV5 | 5/20 | 0.43 |
| ▸ | LIMK2 | P53671 | 1/20 | 0.42 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.42 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.42 |
| ▸ | STS | P08842 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | MMP1 | P03956 | 3/20 | 0.41 |
| ▸ | MMP3 | P08254 | 3/20 | 0.41 |
| ▸ | MMP7 | P09237 | 3/20 | 0.41 |
| ▸ | MMP9 | P14780 | 3/20 | 0.41 |
| ▸ | MMP8 | P22894 | 3/20 | 0.41 |
| ▸ | MMP13 | P45452 | 3/20 | 0.41 |
| ▸ | MMP2 | P08253 | 2/20 | 0.41 |
| ▸ | BMP1 | P13497 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21708266 | 0.95 | TGFBR1 (0.47) | TGFBR1GPR119LIMK2KEAP1NFE2L2 | |
| SCHEMBL21708262 | 0.93 | TGFBR1 (0.49) | TGFBR1GPR119LIMK2KEAP1NFE2L2 | |
| SCHEMBL21708354 | 0.92 | KEAP1 (0.47) | TGFBR1GPR119LIMK2KEAP1NFE2L2 | |
| SCHEMBL21708274 | 0.92 | TGFBR1 (0.48) | TGFBR1GPR119LIMK2KEAP1NFE2L2 | |
| SCHEMBL21734426 | 0.91 | TGFBR1 (0.47) | TGFBR1GPR119LIMK2KEAP1NFE2L2 | |
| SCHEMBL21708330 | 0.88 | TGFBR1 (0.47) | TGFBR1GPR119LIMK2KEAP1NFE2L2 | |
| SCHEMBL21708297 | 0.87 | GPR119 (0.45) | TGFBR1GPR119LIMK2STSMMP1 | |
| SCHEMBL21708367 | 0.85 | MMP13 (0.47) | TGFBR1GPR119LIMK2TSHRMMP13 | |
| SCHEMBL21708321 | 0.85 | KEAP1 (0.42) | KEAP1NFE2L2TSHR | |
| SCHEMBL21708249 | 0.84 | KAT7 (0.47) | TGFBR1KEAP1NFE2L2STSTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210107871-A1 | BIARYL SULFONAMIDE DERIVATIVE HAVING FILOVIRUS CELL ENTRY INHIBITION ACTIVITY | NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY (JP) | 2021-04-15 | — | — | US | disclosed |
| US-20210107871-A1 | BIARYL SULFONAMIDE DERIVATIVE HAVING FILOVIRUS CELL ENTRY INHIBITION ACTIVITY | NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY (JP) | 2021-04-15 | — | — | US | disclosed |
| EP-3611161-A1 | BIARYL SULFONAMIDE DERIVATIVE HAVING FILOVIRUS CELL ENTRY INHIBITION ACTIVITY | National University Corporation Hokkaido University (JP) | 2020-02-19 | — | — | EP | disclosed |
| EP-3611161-A1 | BIARYL SULFONAMIDE DERIVATIVE HAVING FILOVIRUS CELL ENTRY INHIBITION ACTIVITY | National University Corporation Hokkaido University (JP) | 2020-02-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210107871-A1 | BIARYL SULFONAMIDE DERIVATIVE HAVING FILOVIRUS CELL ENTRY INHIBITION ACTIVITY | FLNA, FLNB, BRI3BP | TGFBR1 3849/4885GPR119 1505/4885LIMK2 2539/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.